2018 News Releases
CSL CEO Paul Perreault Earns 2018 Most Admired CEOs Recognition from the Philadelphia Business Journal
Perreault leads the fifth largest biotechnology company in the world with more than 22,000 employees providing lifesaving medicines to patients in more than 60 countries.
New Study Finds Significantly Greater Costs Associated with Multi-Vessel Disease in Medicare Patients Compared to those with Single Vessel Disease following an Acute Myocardial Infarction
Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients
Science Center and Biotech Leader CSL Behring Partner to Accelerate Academic Research in the Search for New Medicines and Possible Cures
Partnership to identify and help commercialize potential new medicines at research and academic institutions across the Greater Philadelphia region
CSL Behring to Feature Secondary Immunodeficiency Symposium at the 2018 Meeting of the European Society for Immunodeficiencies (ESID)
ESID platinum sponsor to partner with experts examining causes of secondary immunodeficiency
CSL Donates to Indonesian Relief Operations
CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts.
CSL Named One of the Top Companies in the World for Diversity and Inclusion
Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index